

United States __tent and Trademark Office

m·H.

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/015,220	10/26/2001	Michael W. Dae	RADNT-031A	6591		
33197	7590 05/21/2003					
STOUT, UXA, BUYAN & MULLINS LLP			EXAMINER			
	4 VENTURE, SUITE 300 IRVINE, CA 92618			HAYES, MICHAEL J		
			ART UNIT	PAPER NUMBER		
			3763	-7		
			DATE MAILED: 05/21/2003	/		

Please find below and/or attached an Office communication concerning this application or proceeding.

				<u> </u>				
	Application No.		Applicant(s)					
	10/015,220		DAE ET AL.					
Offic Action Summary	Examiner		Art Unit					
	Michael J Hayes		3763					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status								
1) Responsive to communication(s) filed on 28.	January 2003 .							
2a) ☐ This action is FINAL . 2b) ☑ Th	is action is non-fina	al.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims								
4)⊠ Claim(s) <u>1-27</u> is/are pending in the application.								
4a) Of the above claim(s) <u>1-18 and 26</u> is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.								
6)⊠ Claim(s) <u>19-25 and 27</u> is/are rejected.								
7) Claim(s) is/are objected to.								
8) Claim(s) are subject to restriction and/o	or election requirem	ent.						
Application Papers	ar.							
9) The specification is objected to by the Examiner.								
10) The drawing(s) filed on <u>26 October 2001</u> is/are: a) accepted or b) objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
1. Certified copies of the priority documents have been received.								
2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) The translation of the foreign language provisional application has been received.								
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. Attachment(s)								
1) Notice of References Cited (PTO-892)	ا الم	Interview Summary	(PTO-413) Paper No	(s).				
2) Notice of Professor's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 1	Notice of Informal P	atent Application (PT					



Art Unit: 3763

DETAILED ACTION

Election/Restrictions

Applicant's election with traverse of Group II, Species 2 in Paper No. 6 is acknowledged. The traversal is on the ground(s) that claim 19 should be considered generic. This is found persuasive and the examiner agrees that claim 19 is generic.

Applicant's election without traverse of claims 19-25 and 27 in Paper No. 6 is acknowledged. Claims 1-18 and 26 are withdrawn. Claim 19 is generic to the two species claimed in claims 26 and 27 respectively.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 19-25 and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over WARD (U. S. Patent No. 5,531,776) in view of DOBAK, III (US 2001/0041923). Ward discloses the use of hypothermia with intra-aortic balloon pumping (5:16-6:65). Ward does not disclose using a heat exchange catheter to achieve the hypothermia or using anti-shivering agents. Dobak teaches the use of a heat exchange catheter inserted in the vena cava to induce hypothermia to 34°C to achieve indirect cooling to chosen organs while preferentially supplying blood to the heart and brain (0017). Dobak also teaches the use of warming blanket or thermoregulatory drugs to limit thermoregulatory defenses during induced hypothermia (0104,

Application/Control Number: 10/015,220

Art Unit: 3763

0105). It would have been obvious to one of ordinary skill in the art at the time of the invention to use the teachings of Dobak in the invention of Ward in order to preferentially cool the patient's organs and to minimize vasoconstriction effects.

Communication

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Hayes at (703) 305-5873. The examiner can usually be reached Monday -Thursday, 7:00-4:30, and on alternate Fridays. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler, can be contacted at (703) 308-3552. The fax number for submitting official papers is (703) 872-9302. The fax number for submitting after final papers is (703) 872-9303.

mjh

19 May 2003

MICHAEL J. HAYES PRIMARY EXAMINER Page 3